单周方案紫杉醇单药治疗在晚期胃癌应用的进展

Development of advanced gastric cancer treated with weekly administration of paclitaxel

晚期胃癌给予化疗加支持治疗,患者的生存率和生活质量都较单独给予支持治疗高。目前,在晚期胃癌治疗中,紫杉醇类的药物是最有前途的细胞毒药物之一。紫杉醇的单药使用,特别是低剂量每周的单药治疗,显示出了令人振奋的作用,且毒副反应较低,起效快,迅速缓解症状,对于一些老年、生存状况差、不适于进行联合化疗,甚至失去常规化疗指征的晚期胃癌患者,不失为一种可供选择的治疗方法。本文着重介绍小剂量每周紫杉醇单药治疗晚期胃癌的一些临床报道。

Benefits in survival and quality of life have been demonstrated in patients with advanced gastric cancer receiving chemotherapy plus optimal supportive care versus optimal supportive care alone . The taxanes, which are among the most promising cytotoxic agents in clinical use have considerable activity in a number of tumor types, Paclitaxel, especially low-dose weekly administration, has shown encouraging activity in the treatment of advanced gastric cancer as a single agent. Patients treated with the low-dose weekly paclitaxel regimen had a statistically superior response rate and time to disease progression as well as clinically significant prolongation of survival. And it offers a new option for those advanced gastric patients such as the aged, poor performance status （PS） or unsuitable for combination chemotherapy, and those even with no indications for rountine chemotherapy. This review is focused on the clinical reports of low-dose weekly administration of paclitaxel for patients with advanced gastric cancer.